PMID- 26432092
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20151104
LR  - 20200930
IS  - 1092-8472 (Print)
IS  - 1092-8472 (Linking)
VI  - 13
IP  - 4
DP  - 2015 Dec
TI  - Novel Therapies in IBS-D Treatment.
PG  - 432-40
LID - 10.1007/s11938-015-0068-5 [doi]
AB  - Irritable bowel syndrome (IBS) is a common gastrointestinal disease characterized 
      by abdominal pain and change in bowel habits. IBS diarrhea predominant (IBS-D), 
      which is arguably the most common subset of IBS, is also associated with rectal 
      urgency, increased frequency, abdominal bloating, and loose to watery stools. 
      Current treatments for diarrhea include mu-opioid agonists (i.e., loperamide, 
      lomotil) and bile acid sequestrants (i.e., cholestyramine) while treatments for 
      abdominal pain include antispasmodics (i.e., hyoscyamine, dicyclomine) and 
      tricyclic antidepressants (i.e., amitriptyline). There are currently 3 
      FDA-approved treatments for IBS-D, which have been shown to improve both 
      abdominal pain and diarrhea. Alosetron was initially approved by FDA 2000; 
      however, its use is now limited to women with severe IBS-D symptoms refractory to 
      other treatment. Eluxadoline, a mixed mu-opioid agonist, and rifaximin, a broad 
      spectrum gut specific antibiotic, were both FDA approved in 2015. Eluxadoline has 
      been shown to relieve abdominal pain and stool consistency in appropriate 
      candidates. While large trials already showed the efficacy of rifaximin in 
      treating non-constipated IBS for bloating, stool consistency, and abdominal pain, 
      the recent TARGET 3 trial demonstrates that retreatment is also effective. While 
      these new treatments significantly expand options for patients suffering from 
      IBS-D, there is likely to remain a need for additional safe and effective 
      therapies.
FAU - Nee, Judy
AU  - Nee J
AD  - Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. 
      jnee@bidmc.harvard.edu.
FAU - Zakari, Mohammed
AU  - Zakari M
AD  - Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
FAU - Lembo, Anthony J
AU  - Lembo AJ
AD  - Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Curr Treat Options Gastroenterol
JT  - Current treatment options in gastroenterology
JID - 9815941
OTO - NOTNLM
OT  - Diarrhea
OT  - Eluxadoline
OT  - Irritable bowel syndrome
OT  - Rifaximin
OT  - Treatment
EDAT- 2015/10/04 06:00
MHDA- 2015/10/04 06:01
CRDT- 2015/10/04 06:00
PHST- 2015/10/04 06:00 [entrez]
PHST- 2015/10/04 06:00 [pubmed]
PHST- 2015/10/04 06:01 [medline]
AID - 10.1007/s11938-015-0068-5 [pii]
AID - 10.1007/s11938-015-0068-5 [doi]
PST - ppublish
SO  - Curr Treat Options Gastroenterol. 2015 Dec;13(4):432-40. doi: 
      10.1007/s11938-015-0068-5.